CELEBREX

Compare CELEBREX  to:
Compare
Compare

Generic Name for CELEBREX

Celecoxib 50mg, 100mg, 200mg, 400mg; caps.

Legal Classification:

Rx

Pharmacological Class for CELEBREX

NSAID (COX-2 inhibitor).

Manufacturer of CELEBREX

Pfizer Labs

Indications for CELEBREX

Acute pain.

Adult dose for CELEBREX

≥18yrs: 400mg once then 200mg more on 1st day if needed, then 200mg twice daily. <50kg: start at lowest recommended dose.

Children's dosing for CELEBREX

Not recommended.

Contraindications for CELEBREX

Sulfonamide or aspirin allergy. 3rd trimester pregnancy. Coronary artery bypass graft surgery.

Precautions for CELEBREX

Advanced renal disease or severe hepatic impairment: not recommended. Renal or liver dysfunction; reduce dose by 50% in moderate hepatic insufficiency (Child-Pugh class B). Discontinue if liver disease or systemic effects (eg, eosinophilia, rash) develops. History or risk of GI bleed/ulcer (monitor). Fluid retention. Heart failure. Hypertension. Asthma. Alcoholism. Dehydrated. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for CELEBREX

Caution with drugs that inhibit CYP2C9 (eg, fluconazole) or are metabolized by CYP2D6. May antagonize, or increase risk of renal failure with ACEIs, diuretics. Increased risk of GI bleed with aspirin (except low-dose), corticosteroids, smoking, anticoagulants. May potentiate lithium. Monitor warfarin.

Adverse Reactions for CELEBREX

GI upset/pain, edema, pharyngitis, increase AST/ALT, GI ulcer/bleed; rare: intracranial bleed, liver failure. See literature re: risk of cardiovascular events.

How is CELEBREX supplied?

Caps 100mg, 200mg—100, 500
50mg, 400mg—60

Related Disease:

Pain, general~nonnarcotics

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

McNeil Consumer Healthcare recalls certain over-the-counter (OTC) products

January 15, 2010

McNeil Consumer Healthcare and the FDA have announced a voluntary recall of certain lots of over-the-counter products, including Tylenol (acetaminophen), Motrin IB (ibuprofen), St. Joseph Aspirin (aspirin), Simply Sleep (diphenhydramine), and Rolaids (calcium carbonate and magnesium hydroxide).

Naprelan Dose Card blister packs launched

November 23, 2009

Victory Pharma announces the availability of Naprelan (naproxen) Dose Card, a single blister pack which provides a ten day, tapered dose regimen of naproxen.

Phase 2 study of Civamide Patch for post-herpetic neuralgia (PHN)

November 16, 2009

Winston Laboratories announced positive top-line results from Study WL1001-04-03, a Phase 2 clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide in the treatment of post-herpetic neuralgia (PHN).

Lusedra available for monitored anesthesia care sedation

November 16, 2009

Eisai has made available Lusedra (fospropofol disodium injection), an intravenous water-soluble prodrug of the sedative-hypnotic agent propofol, for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.